Document:

EX-10.2

 Exhibit 10.2 
  

 
 The Terms and Conditions of 

the ProQR Therapeutics N.V. 
 Stock Option Plan 

Subject to the listing and the admission to trading of the Company’s ordinary shares on the NASDAQ Global Market and subject to supervisory board
approval 

 Contents 
  

							
	 RULE 1
	 	DEFINITIONS	  	 	3	  
			
	 RULE 2
	 	INTERPRETATION	  	 	6	  
			
	 RULE 3
	 	POWERS OF THE SUPERVISORY BOARD AND MANAGEMENT BOARD	  	 	7	  
			
	 RULE 4
	 	GRANT AND VESTING OF OPTIONS	  	 	7	  
			
	 RULE 5
	 	RIGHTS OF EXERCISE AND LAPSE OF OPTIONS	  	 	9	  
			
	 RULE 6
	 	MANNER OF EXERCISE	  	 	10	  
			
	 RULE 7
	 	FAIR MARKET VALUE	  	 	10	  
			
	 RULE 8
	 	NON–TRANSFERABILITY AND NATURE OF THE OPTIONS	  	 	10	  
			
	 RULE 9
	 	RELEASE OF SHARES	  	 	11	  
			
	 RULE 10
	 	LOSS OF OFFICE OR EMPLOYMENT	  	 	11	  
			
	 RULE 11
	 	TAX AND SOCIAL SECURITY	  	 	12	  
			
	 RULE 12
	 	VARIATION OF CAPITAL	  	 	13	  
			
	 RULE 13
	 	CHANGE OF CONTROL OF THE COMPANY	  	 	13	  
			
	 RULE 14
	 	PLAN AMENDMENTS AND SPECIAL PROVISIONS	  	 	14	  
			
	 RULE 15
	 	NOTIFICATION	  	 	14	  
			
	 RULE 16
	 	INSIDER TRADING RULES	  	 	15	  
			
	 RULE 17
	 	DISPUTES	  	 	15	  
			
	 RULE 18
	 	COSTS OF THE PLAN	  	 	15	  
			
	 RULE 19
	 	GOVERNING LAW	  	 	15	  

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(2)

	Rule 1	Definitions 

 In the Rules of this Plan, unless the context otherwise requires, the following words and
expressions shall have the meanings as set out below: 
  

			
	Articles of Association	  	the articles of association of the Company as amended from time to time;
		
	Business Day	  	a day which is not a Saturday or a Sunday and which is not a public holiday or a bank holiday in the Netherlands;
		
	Cause	  	in the context of termination of a Participant’s status as an employee or officer of the Group or as a service provider to the Group, a reason which constitutes a serious cause on the side of the Company within the meaning of
Article 7:679 of the Dutch Civil Code, or other serious cause representing a material breach under the employment, service or other relevant agreement or engagement entered into with that Participant;
		
	Cause by the Individual	  	in the context of termination of a Participant’s status as an employee or officer of the Group or as a service provider to the Group, a reason which constitutes an urgent cause on the side of that Participant within the meaning
of Article 7:678 or serious cause on the side of that Participant within the meaning of Article 7:685 of the Dutch Civil Code, other serious cause on the side of that Participant representing a material breach under the employment, service or other
relevant agreement or engagement entered into with that Participant or a material breach by that Participant or his fiduciary tasks and duties towards the Company or the relevant group Company;
		
	Committee	  	such person or committee of persons and successor person or successor committee of persons appointed by the Supervisory Board to whom the Supervisory Board has delegated any of its powers under this Plan;
		
	Company	  	the public company with limited liability ProQR Therapeutics N.V., having its office address at Darwinweg 24, 2333 CR Leiden, the Netherlands, registered with the Dutch Chamber of Commerce under registration number
54600790;
		
	Compensation Policy	  	the compensation policy for the Management Board of the Company, as adopted by the General Meeting and as amended from time to time;
		
	Control	  	in respect of the Company or a Group Company, the ability to (i) alone or together with one or more subsidiaries, whether or not in concert with others, exercise or cause to exercise more than one-half of the voting rights in the
shareholders’ or members’ meeting of the Company or such Group Company, or (ii) the ability to appoint more than one-half of the directors or supervisory directors of the Company or such Group Company, or (iii) to exercise decisive
influence with regard to the general course of affairs of the Company or such Group Company;

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(3)

			
		
	Date of Grant	  	the date on which one or more Options is/are offered to an Eligible Individual by the Company, which shall be the date specified in the Notice of Grant;
		
	Effective Date	  	                 , 2014;
		
	Eligible Individual	  	an Individual, not being a member of the Management Board or a member of the Supervisory Board, who has been selected by the Management Board to receive a Grant under the Plan; or an Individual being a member of the Management Board
or a member of the Supervisory Board who has been selected by the Supervisory Board to receive a Grant under the Plan;
		
	Exercise Period	  	the period during which a Vested Option can be exercised, as specified in the Notice of Grant;
		
	Exit	  	a Sale, Liquidation or any combination thereof;
		
	Fair Market Value	  	the market value of one Share as appropriate, as specified in Rule 7 of this Plan;
		
	General Meeting	  	the Company’s general meeting of shareholders as mentioned in the Articles of Association;
		
	Grant	  	one or more Options granted to Participants in accordance with or as a result of an Eligible Individual’s participation in the Plan;
		
	Group	  	the Company and its Group Companies;
		
	Group Company	  	any subsidiary or group company of the Company as defined in Articles 2:24a and 2:24b of the Dutch Civil Code, as may change from time to time;
		
	Individual	  	any individual who has entered into employment or position with the Company or any Group Company; or an individual (whether or not through the use of a company of which that individual is the sole shareholder) that provides
management and/or consulting services for the Company or a Group Company; or an individual who is appointed as an officer of the Company or of any Group Company or any other person as determined by the Supervisory Board;
		
	Insider Trading Rules	  	the internal code of conduct to be adopted by the Company or a Group Company on insider trading, as may be amended from time to time and/or the securities laws and regulations (including applicable stock exchange or listing rules)
in the jurisdiction(s) where Shares or other securities issued by the Company or shares or other securities issued by a Group Company (or rights derived thereof) are and/or may be listed to the extent these relate to insider
trading;

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(4)

			
		
	IPO	  	the listing and the admission to trading of the Company’s ordinary shares on the NASDAQ Global Market;
		
	Liquidation	  	the liquidation, dissolution or other reorganization of the Company resulting in the Company’s shareholders receiving cash or liquid securities as consideration or proceeds in excess of the aggregate subscription price and
dividends payable in respect of the Shares held by them;
		
	Management Board	  	the Company’s management board as mentioned in the Articles of Association;
		
	Notice of Exercise	  	a notice to the Company in a form to be determined by the Supervisory Board whereby a Participant exercises an Option granted to him under the Rules of this Plan;
		
	Notice of Grant	  	a notice to an Eligible Individual in a form to be determined by the Supervisory Board whereby one or more Options under this Plan are granted and for an Eligible Individual being a member of the Management Board or a member of the
Supervisory Board, taking into consideration the compensation granted to him and, in general, Compensation Policy;
		
	Option	  	the right to acquire one (1) Share against payment of the Option Price during the Exercise Period, which right is granted to a Participant under the Rules of this Plan;
		
	Option Price	  	the price per Share, as determined by the Supervisory Board at the Date of Grant, in respect of which an Option may be exercised, which shall be the Fair Market Value at the Date of Grant, or such other price per Share as specified
in the relevant Notice of Grant, provided that the Option Price per Share shall not be lower than the nominal value of the Share;
		
	Participant	  	an Eligible Individual who has been offered and has accepted a Grant under the Rules of this Plan;
		
	Performance Condition	  	one or more performance targets, if any, as set at the Date of Grant specified in the relevant Notice of Grant that should be attained during the relevant Performance Period in order to determine the level of Vesting of a Grant on
the relevant Vesting Date;
		
	Performance Period	  	the period, as determined in the relevant Notice of Grant, over which the attainment of Performance Conditions is measured;
		
	Plan	  	the ProQR Therapeutics N.V. Stock Option Plan in its present form or as from time to time amended, in accordance with the provisions hereof;
		
	Release	  	the issuance (‘uitgifte’) or transfer (‘levering’) of Shares to a Participant, and “Released” and “Release Date” shall be construed and interpreted
accordingly;

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(5)

			
		
	Retirement	  	retirement at the normal statutory retirement age in a given country at which the relevant Individual becomes entitled to a state old age pension. This statutory retirement age can only be lowered if and to the extent that the
Individual is entitled to a form of early retirement on the basis of an individual agreement or collective agreement on Company or Group Company level or in case the Supervisory Board grants an individual exemption and approves such early
retirement;
		
	Rules	  	the rules governing the operation of the Plan as may be amended from time to time;
		
	Sale	  	the sale of more than 50% of the Shares or the sale, lease or licensing out of all or a substantial part of the Company’s assets resulting in the Company no longer exclusively controlling such assets or any other event
resulting in a change of Control over the Company;
		
	Share	  	an ordinary share in the capital of the Company, having a nominal value of EUR 0.04 or any other nominal value such Share may have in the future;
		
	Stock Exchange	  	NASDAQ Global Market or any other market the Shares are listed.
		
	Supervisory Board	  	the Company’s supervisory board as mentioned in the Articles of Association;
		
	Total and Permanent Disability	  	the mental or physical disability, whether occupational or non-occupational in cause, which satisfies such definition in any insurance policy or plan provided to a Participant by the Company or a Group Company, or, alternatively,
the relevant Participant’s applicable national legislation pertaining to persons with disability;
		
	Vesting	  	the satisfaction of the requirements of Rule 4 of this Plan, and ‘Vested’ and ‘Vest’ shall be construed accordingly; and
		
	Vesting Date	  	the date on which Options shall Vest, in whole or in part, as determined by the Supervisory Board and as specified in the Notice of Grant and pursuant to Rule 4 of this Plan.

  

	Rule 2	Interpretation 

 Words or expressions used in the Plan shall where appropriate: 

 

	(i)	when denoting the masculine gender include the feminine and vice versa; 

  

	(ii)	when denoting the singular include the plural and vice versa; 

  

	(iii)	when referring to any enactment be construed as a reference to that enactment as for the time being consolidated, amended, re-enacted or replaced and shall include any regulations made there under; 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(6)

	(iv)	when a period of time is specified and starts from a given day or the day of an act or event, be calculated inclusive of that day; 

  

	(v)	be construed such that the headings and sub-headings are for ease of reference only, and do not affect the interpretation of any Rule; 

 

	(vi)	when referring to any enactment or regulations under Dutch law be construed at the discretion of the Supervisory Board as a reference to other (analogous) applicable laws or regulations of any other country (or region
of a country); 

  

	(vii)	references to tax and/or social security contributions and/or withholding taxes shall for the avoidance of doubt include those applicable under the laws of the Netherlands and any other jurisdiction to which a
Participant may be subject; 

  

	(viii)	when a period of time is specified and ends on a day which is not a Business Day, the end day of such period will be extended to the next Business Day; and 

 

	(ix)	when referring to an ‘officer’ this will be construed as including a reference to directors of subsidiaries and members of a supervisory board and references to someone holding “office” shall be
interpreted accordingly. 

  

	Rule 3	Powers of the Supervisory Board and Management Board 

  

	3.1	The Plan shall be administered by the Supervisory Board. 

  

	3.2	The Supervisory Board shall have such powers and authority delegated to it as set out in the Plan and is responsible to take the Compensation Policy into account. The Supervisory Board may determine as soon as
practicable after the Effective Date if, how and to what extent any of their powers shall be delegated to (or revoked from) any Committee. After such delegation, the Committee shall have such powers and authority delegated to the Supervisory Board
as set out in the Plan in order to administer the Plan, until such time as the Supervisory Board has revoked such powers and authority. 

  

	3.3	The Company shall have the authority and complete discretion to decide whether or not to make Grants under the Plan to Individuals, subject to Rule 3.4, and decide what percentage of the outstanding Shares will be used
to give effect to such Grants. 

  

	3.4	The Management Board may select Individuals, not being members of the Management Board or members of the Supervisory Board and effect such Grants, as Eligible Individuals and the Supervisory Board may select Individuals
being members of the Management Board or members of the Supervisory Board, as Eligible Individuals and make such Grants to them taking into account their respective compensation and the Compensation Policy in general. 

 

	3.5	Notwithstanding Rules 3.1, 3.2 and 3.3, the Supervisory Board shall have the authority and complete discretion to construe and interpret the provisions of the Plan, any Notice of Grant or any Notice of Exercise and any
other agreement or document executed pursuant to the Plan. 

  

	Rule 4	Grant and Vesting of Options 

  

	4.1	Subject to Rules 3.3 and 3.4, the Management Board or the Supervisory Board, as the case may be, can offer Options to Eligible Individuals at any time on or after the Effective Date. 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(7)

	4.2	Notwithstanding Rule 4.1, Notices of Grants are concluded on a discretionary basis. A Grant shall therefore not be construed to give any Participant the right to receive future Grants. 

 

	4.3	Each Grant shall be evidenced by a signed Notice of Grant concluded between the Participant and the Company, setting forth the terms and conditions pertaining to such Grant. The Notice of Grant shall be available in
each of the countries in which the Plan is operational and shall, together and concurrently with the Rules, govern the Grant in accordance with local legal and regulatory requirements and the stock exchange or listing rules to the extent applicable.

  

	4.4	Each Notice of Grant shall include a schedule describing the date(s), event(s) or act(s) upon which an Option shall Vest in whole or part or become exercisable and shall further specify: 

 

	 	(a)	the Option Price; 

  

	 	(b)	the number of Shares subject to the Grant; 

  

	 	(c)	any Performance Conditions and Performance Period that may be imposed and attached to the Vesting of the Options; 

  

	 	(d)	the Exercise Period; 

  

	 	(e)	the Date of Grant; 

  

	 	(f)	the Vesting Period; and 

  

	 	(g)	the date on which the Option(s) to which the Grant pertains will lapse. 

  

	4.5	If an Eligible Individual wishes to participate in the Plan, he is required to return a signed copy of the Notice of Grant to the Company or a party designated by the Company within fourteen (14) days following the
date on which the offer is made. Options that are not accepted in full and in accordance with this Rule 4.5, will lapse automatically with immediate effect and without any consideration becoming due. By accepting a Grant the Participant accepts the
Rules and all other regulations and documents relating to the Grant. 

  

	4.6	Vesting of the Options is subject to the attainment of any Performance Conditions imposed and to the Participant remaining an Eligible Individual with continued employment or office with or providing services to the
Company or any Group Company until the end of each of the respective Vesting Dates. Such Vesting conditions are specified in the relevant Notice of Grant. Once all Vesting conditions have been satisfied, the Options Vest. The relevant Notice of
Grant specifies on which date the fulfilment of the relevant conditions of Grants will be measured and/or determined. The attainment of the Performance Conditions and the satisfaction of the other Vesting conditions shall be determined by the
corporate body or Committee which granted the Options at its discretion. 

  

	4.7	If a Participant ceases to be an Eligible Individual: 

  

	 	(i)	due to his death; 

  

	 	(ii)	as a consequence of his Total and Permanent Disability or Retirement; 

  

	 	(iii)	Cause; or 

  

	 	(iv)	any other individual situation determined by the Supervisory Board at its discretion, 

 the
Supervisory Board may, in its sole discretion and acting reasonably, determine that a portion of the outstanding Options that are not Vested held by that Participant will Vest at the date such Participant ceases to be an Eligible Individual and to
determine during what period that Participant’s Vested Options will remain outstanding (if relevant, for the benefit of the Participant’s legal successor(s) in 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(8)

 
case of death in accordance with Rule 8 of this Plan) whereby this period will not exceed the remaining Exercise Period as specified in the relevant Notice of Grant. In determining such portion
the Supervisory Board may take into consideration the period to the date of the Participant ceasing to be an Eligible Individual. After the expiry of the period during which the Vested Options can be exercised as determined in accordance with this
Rule 4.7, the Options will lapse automatically without any consideration becoming payable. In case of death of the Participant, the Supervisory Board may at its sole discretion also determine to cancel all outstanding Options (whether Vested or not)
and pay (for the benefit of that Participant’s legal successor(s)) with respect to each of these Vested Options the (positive) difference between the Fair Market Value of a Share at the date of cancellation and the Option Price. 

 

	4.8	Ultimate remedium and claw back – The Supervisory Board has for grants of Options made to members of the Management Board the authority to adjust the number of unvested Options and/or to fully or
partially recover Vested Options subject to the terms and conditions as contained in or applicable to the Notice of Grant and in general with due observance of Article 2:135 (6) and (8) of the Dutch Civil Code. 

 

	Rule 5	Rights of Exercise and Lapse of Options 

  

	5.1	Subject to Rules 4.5 to 4.7, Vested Options will become exercisable during the Exercise Period as specified in the Notice of Grant, except in case of an Exit in which case all Options (whether Vested or not) will become
exercisable immediately following the occurrence of such Exit, unless otherwise provided for by Rule 13, or will Vest accelerated in accordance with Rule 4.7. 

  

	5.2	If a Participant ceases to be an Eligible Individual for any reason other than those set out in Rules 4.7 and 5.3, all the outstanding Options held by that Participant that are not Vested at the date such
Participant ceases to be an Eligible Individual shall lapse immediately at that time without any consideration becoming due. Notwithstanding Rule 5.1, the Participant’s Vested Options are exercisable thirty (30) days or, in case of the
death of that Participant, ninety (90) days following the date such Participant ceases to be an Eligible Individual within the Exercise Period. After this thirty day or ninety day period (or, if earlier, upon the expiry of the Exercise Period),
these Vested Options will lapse automatically without any consideration becoming due. 

  

	5.3	In case of termination of employment or office for Cause by the Individual, all the Options granted, irrespective of whether or not these Options have Vested, shall immediately lapse at the date of such termination of
employment or office, without any consideration becoming due. 

  

	5.4	 Subject to Rules 4.7, 5.2 and 5.5 of this Plan, the Supervisory Board may extend the periods during which Options held by a Participant are
exercisable following the date such Participant ceases to be an Eligible Individual as described in Rules 4.7 and 5.2, if such an exercise would temporarily be prohibited by law, securities regulations, stock exchange or listing rules, or any
applicable Insider Trading Rules. Such period during which the relevant Options are exercisable shall be extended by the length of such period of prohibition. This may apply differently if the Supervisory Board, acting reasonably and given the
specific circumstances of the Participant, determines otherwise, in which event the Supervisory Board in its sole discretion and acting reasonably, shall determine the extent, and the terms, of the Participant’s continued participation in the
Plan, including, without limitation, 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(9)

	 	
the number of Shares to which his Options pertain and the remaining period during which those Options are exercisable). 

 

	5.5	All outstanding Options of a Participant, whether Vested or not, shall lapse immediately and automatically, without any consideration becoming due, upon the occurrence of the earliest of the following events with
respect to those Options or that Participant: 

  

	 	(i)	the tenth anniversary of the Date of Grant; 

  

	 	(ii)	the expiry of any of the applicable periods specified in Rules 4.7, 5.2, 5.4 and 6.4; 

  

	 	(iii)	the date of termination of employment or office in case of termination of employment or office for Cause by the Individual pursuant to Rule 5.3; 

 

	 	(iv)	the expiry of any of the periods which are determined on the basis of any adjustments made in respect of the events as specified in Rules 13 and 14; 

 

	 	(v)	the Participant’s attempted assignment, transfer or encumbrance of any of his Options other than as permitted under Rules 8 and 13 or in case of another material breach by the Participant of the Rules, unless
otherwise determined at the discretion of the Supervisory Board. 

  

	Rule 6	Manner of Exercise 

  

	6.1	Subject to Rules 4.7, 5.2, 5.4 and 6.4 of this Plan, a Grant may be exercised during the Exercise Period after the Options have Vested in accordance with Rule 4.6 and before the Option(s) to which the Grant pertains
lapse(s) in accordance with Rules 4.7 and 5. A Grant can only be exercised in full. 

  

	6.2	Subject to the Rules, an Option may be exercised by the signing of a Notice of Exercise by the Participant which will be effective upon receipt of the signed Notice of Exercise by the Company or a party designated by
the Company. 

  

	6.3	Subject to the Rules of this Plan, the Company shall as soon as practicable following the receipt of the Notice of Exercise and the payment of the Option Price for the relevant Option(s) Release the Shares covered by
the Option(s) specified in the Notice of Exercise in accordance with Rule 9 and 11.3. 

  

	6.4	Each exercise of an Option is subject to the Insider Trading Rules. Subject to Rule 5.4, where the exercise of any Option would temporarily be prohibited by law, securities regulations, stock exchange or listing rules,
or any applicable Insider Trading Rules, the Exercise Period shall be extended with the length of such period of prohibition provided that such Option may not be exercised after the expiry of that Option in accordance with any other Rule of this
Plan. 

  

	Rule 7	Fair Market Value 

 The Fair Market Value on a certain date shall be the closing price of one
(1) Share (or similar security) as quoted on the Stock Exchange on the last preceding Business Day on which trade in the Shares took place. 
  

	Rule 8	Non–transferability and nature of the Options 

 A Grant made to a Participant is strictly personal
and shall, if the Option(s) to which such Grant pertains are Vested and during the lifetime of the Participant, be exercisable by the Participant alone and shall not be 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(10)

 
assignable or transferable and cannot be charged, pledged, encumbered or otherwise used for the purpose of creating security title or interest of whatever nature. The Company is under no
obligation required to repurchase any Options and/or any Shares pursuant to these Rules. In the event of the Participant’s death, such Participant’s Options are transferable to the Participant’s beneficiaries only by last will and
testament or by the applicable hereditary laws. In all other events any attempted assignment, transfer or encumbrance by a Participant shall be null and void shall cause such Participant’s Option(s) to lapse with immediate effect. 

 

	Rule 9	Release of Shares 

  

	9.1	Subject to Rule 6.3 of this Plan, the Company shall Release the Shares to the Participant pursuant to the exercise of an Option as soon as practicable following (i) the date the Participant has returned the Notice
of Exercise signed by the Participant, and (ii) the payment of the relevant Option Price. The Release is subject to (i) receipt of all required statutory approvals under the relevant laws and regulations and any listing rules of the stock
exchanges where Shares (or rights derived therefrom) are traded and (ii) any applicable Insider Trading Rules. If the Participant has indicated that he wishes to apply the exercise immediate sell method or the sell to cover method for funding
the tax liability in accordance with Rule 11.3, the Company shall calculate the number of Shares to be sold under the exercise immediate sell method or sell to cover method, facilitate the sale of such Shares in accordance with Rule 11.3 and
transfer the remainder of the cash proceeds following the exercise immediate sell method or the remainder of the Shares under the sell to cover method to the Participant. The remainder of the Shares shall be Released to the Participant concerned.

  

	9.2	A Participant shall not be entitled to any compensation of damage or losses insofar as such damage or losses arise(s) or may arise from a delayed Release under this Rule 9, unless it has been delayed unreasonably by the
Company. 

  

	9.3	Participants are only permitted to sell, transfer or encumber the Shares acquired by them in accordance with the provisions of the applicable Insider Trading Rules. 

 

	Rule 10	Loss of office or employment 

  

	10.1	The Plan does not form part of the Participant’s employment agreement or service agreement or other engagement with the Company or with any Group Company, and shall not be construed to give any Participant the
right to remain in the employ of or continue to provide services to or continue to be an officer of the Company or any Group Company. 

  

	10.2	A Grant made to a Participant cannot be considered to be a guarantee to that Participant that the employment or office of that Participant with the Company or any other Group Company, or the providing of services by the
Participant to the Company or to any Group Company will continue. 

  

	10.3	Any benefits derived by a Participant under this Plan shall not be taken into account for the purposes of determining that Participant’s contribution or entitlement to benefits under any retirement arrangement or
for the purposes of determining any other claim for compensation that Participant may have against the Company or against any Group Company. 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(11)

	10.4	Where the employment, office or service agreement with the Company or a Group Company of a Participant terminates for whatever reason, that Participant shall not be entitled to any compensation or damages (including
damages following unfair dismissal), any other form of breach of contract or any claim for compensation for the loss of employment, office or services insofar as such compensation or damages arise or may arise from the Participant ceasing to have
rights under this Plan as a result of such termination. The Plan shall not at any time affect the rights of the Company or a Group Company (or their relevant corporate bodies) to terminate such Participant’s status as an officer, an employee or
a service provider, whether with or without Cause. 

  

	10.5	A Grant shall not entitle nor preclude the Participant to whom that Grant was awarded from participating in another Grant under the Plan or participation in any other plan operated by the Company or any Group Company.

  

	Rule 11	Tax and social security 

  

	11.1	All applicable personal tax (e.g. any wage tax or income taxes) and employee social security levies as a consequence of or resulting from the Grant of one or more Options, including, for the avoidance of doubt, as a
consequence of or resulting from the exercise or Vesting of any Option, or in respect of the implementation of the Plan shall be borne by the relevant Participant. 

 

	11.2	Each Participant shall permit the Company or any Group Company to withhold and account for an amount equal to any wage tax or income tax, employee’s social security contributions liability and any other liabilities
for which the Company or a Group Company as the case may be, has an obligation to withhold and account. In case an Option is cancelled for whatever reason, the relevant Participant will not be compensated for any taxes or employee social security
levies (to be) paid in connection with that Option or the cancellation thereof. 

  

	11.3	In order to facilitate the funding of the wage tax, income tax and employee social security levies to be withheld upon exercise of the Options, the Company shall allow the Participant to sell, without further action by
the Company, all or sufficient Shares Released to such Participant to cover the relevant tax and social security liability (“exercise immediate sell” or “sell to cover” method) at such exercise. The sale proceeds from the
application of such exercise immediate sell transaction or sell to cover transaction, after deduction of costs, shall be used to satisfy the withholding liability. The remainder of the cash proceeds or any rounding differences shall be paid in cash
by the Participant. 

  

	11.4	The Plan is governed by the tax and social security legislation and regulations prevailing as at the date a certain taxable event occurs. If any tax and/or employee social security legislation or regulations are amended
and any tax or employee social security levies become payable as a result of such legislative amendment, the costs and the risks related thereto shall be borne solely by the relevant Participant. 

 

	11.5	Where, in relation to an Option granted under this Plan, the Company or any Group Company (as the case may be) is liable, or is in accordance with current practice believed by the Supervisory Board to be liable, to
account for any tax or social security authority for any sum in respect of any tax or social security liability of the Participant, the Option may not be exercised unless the relevant Participant has paid to the Company or the Group Company (as the
case may be) an amount sufficient to discharge the liability. 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(12)

	11.6	For the avoidance of doubt, the provisions of Rules 11.1 to 11.5 shall apply to a Participant’s liabilities that may arise on a taxable event in any jurisdiction. 

 

	Rule 12	Variation of Capital 

  

	12.1	Subject to the Articles of Association, in the event of a share split, reverse share split, any capitalisation issue, distribution of, extraordinary dividend, rights issue, issue of benefit, or bonus Shares, or rights
offer or any reduction, sub-division, consolidation or other variation of the capital of the Company the number of Options subject to any Grant and/or the Option Price, as the case may be, may be adjusted by the Company without prejudice (including
retrospective adjustments where appropriate) in such manner as the Company considers to be in its opinion fair and reasonable, or take whatever other reasonable actions the Supervisory Board considers appropriate, it being understood that such
actions may include an additional grant of the rights and/or securities to the relevant Participants, under the same conditions as apply to the variation of capital concerned. 

 

	12.2	Notice of any adjustment referred to in Rule 12.1 shall be given by the Company to those Participants affected by such adjustment. The Participant shall receive such a notice within one month following the date the
adjustment has been made. 

  

	Rule 13	Change of Control of the Company 

  

	13.1	Subject to the Articles of Association, required approval of the relevant corporate body, bodies or Committee(s) of the Company and any applicable laws or regulations, in the event of an Exit, a merger, split, or
consolidation or similar transaction in relation to the Company, a change in Control of the Company or a share-for-share exchange involving the Company, the Supervisory Board shall have the power to decide to: 

 

	 	(i)	provide for the exchange of each Option outstanding immediately prior to such event for options with respect to some or all of the property for which securities are exchanged in such transaction and, as a result, make
any necessary equitable adjustment in the Option Price of the new options, or the number of securities or amount of property subject to the Options or, as appropriate, provide for a cash payment to the Participants to whom such Options were granted
in partial consideration for the exchange of the Options; and/or 

  

	 	(ii)	accelerate Vesting of all the outstanding Options effective immediately prior to the occurrence of such event; and/or 

  

	 	(iii)	effective immediately prior to the occurrence of such event, cancel each outstanding Option and pay the Participants, for each of their respective Options thus cancelled, the (positive) difference between the underlying
Fair Market Value of a Share at the date of cancellation and the Option Price; and/or 

  

	 	(iv)	take whatever other reasonable steps the Supervisory Board considers appropriate. 

  

	13.2	Subject to Rule 13.1 all adjustments and/or payments described in Rule 13.1 shall be made by the Supervisory Board and shall be reviewed and approved by an independent advisor appointed by the Supervisory Board. Such
approval shall be conclusive and binding on all persons. 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(13)

	13.3	Except as expressly provided in Rules 12 and 13, no Participant shall be afforded any rights by reason of any capital or corporate reorganisation of the Company or any other transaction as set out in Rule 13.1.

  

	13.4	Except as expressly provided in Rules 12 and 13, a Grant effected pursuant to the Plan shall not affect in any way the right or power of the Company or any Group Company to effect any capital or corporate
reorganisation. 

  

	13.5	If an event occurs constituting a change of Control of a Group Company due to which the Participant is no longer employed with or an officer of or no longer provide(s) service to the Group, the Supervisory Board can at
its absolute discretion provide for any adjustments or payments as deemed appropriate such as, inter alia, continuation of the Plan or settlement of the outstanding Options of the Participant immediately prior to such event.

  

	Rule 14	Plan amendments and special provisions 

 Subject to the Articles of Association, the Supervisory Board
acting reasonably may from time to time at its discretion amend or waive any requirement or conditions under any of the Rules, the Notice of Grant and/or the Notice of Exercise. 

 

	Rule 15	Notification 

  

	15.1	The administration of the Plan will be executed by the Company or a third party administrator as appointed by the Company. 

  

	15.2	Any notice or other document required to be given to any Participant with respect to the operation of this Plan shall be delivered to him at his home address or such other address as may appear to the Company to be
appropriate, or by e-mail message or in any other format agreed in advance between the Participant and the person giving the notice on behalf of the Supervisory Board. Any notice or other document required to be given to the Company or the
Supervisory Board shall be delivered in a format agreed in advance between the Participant and the person receiving the notice. 

  

	15.3	In the execution of the Plan, the Company will respect and comply with applicable data protection laws. Each Participant consents by the acceptance of the Grant to the processing, collection, recording, organising,
storing and adapting of personal data by the Company or third party administrators involved in the operation and administration of the Plan and for that purpose only. This may also include transferring such information to countries or territories
that fall outside of the European Economic Area and which may not provide the same level of data protection as the European Economic Area or the Participant’s home country. The Company may also keep the personal data of each Participant to
comply with statutory retention periods. Each Participant acknowledges that this may restrict the Participant’s rights. Each Participant has the right to access and/or correct personal data, if and when necessary, by contacting the Company.

  

	15.4	The Supervisory Board may, at its absolute discretion, issue written guidance setting out the procedures whereby the Plan shall be operated. 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(14)

	Rule 16	Insider Trading Rules 

  

	16.1	Participants and the Company shall be subject to and bound by the terms and conditions of any Insider Trading Rules. Such Insider Trading Rules may restrict the rights of the Participants and/or the Company under this
Plan. 

  

	16.2	Participants are deemed to be familiar and are responsible for complying with any applicable Insider Trading Rules and any other information, guidance and/or regulations issued by the Company or relevant government or
regulatory bodies. The Company shall incur no liability should a Participant act in breach of any Insider Trading Rules or any other information, guidance and/or regulations issued by the Company or relevant government or regulatory bodies.

  

	Rule 17	Disputes 

 The decision of the Supervisory Board, in any dispute or question relating to any Grant shall
be final and conclusive subject to the terms of this Plan. The provisions of a Notice of Grant shall govern and prevail in the event of any conflict with the Rules. 
  

	Rule 18	Costs of the Plan 

 Without prejudice to Rule 11, the costs of introducing, operating and administering
this Plan shall be borne by the Company. Any cost incurred with respect to the application of the exercise immediate sell method or sell to cover method as described in Rule 11.3, shall be borne by the Participant. 

 

	Rule 19	Governing law 

 This Plan shall be governed by and shall be construed in accordance with the law of The
Netherlands. The Company and each Participant hereby irrevocably submit, in respect of any suit, action or proceeding related to the implementation or enforcement of this Plan, shall be settled by the Court of Amsterdam the Netherlands. 

* * * 

  

			
	ProQR Therapeutics N.V. Stock Option Plan	  	(15)

 

 
 Notice of Grant 

Mr. / Ms. [name] 

[address]  

[postal code] [place][country] 

[Insert date]  
  

	Subject:	the Grant of Options pursuant to the ProQR Stock Option Plan 

 Dear [name of Participant], 

I am pleased to let you know that you are hereby made an offer to be granted Options to acquire Shares as further specified below under the terms and
conditions applicable to the ProQR Therapeutics N.V. Stock Option Plan (the ‘Plan’). 
 The definitions used in this Notice of Grant have the same
meaning as the definitions used in the Plan, as attached hereto. Subject to the Rules of the Plan, you are granted Options on the following conditions: 
  

					
	Date of Grant:	 	[date]
		
	Options granted:	 	[number]
		
	Number of underlying Shares:	 	[same number]
		
	Option Price:	 	[EUR price]
		
	Vesting Dates:	 	Vesting of the Options is subject to continued employment or office as stated in the Rules of the Plan, and in particular Rules 4 and 5. If you remain employed, the Options will Vest in four equal annual tranches as
follows:
			
		 	•	  	25% on the first anniversary of the Date of Grant;
			
		 	•	  	25% on the second anniversary of the Date of Grant;
			
		 	•	  	25% on the third anniversary of the Date of Grant;
			
		 	•	  	25% on the fourth anniversary of the Date of Grant.
		
	Exercise Period:	 	Subject to what has been stated for specific circumstances in the Rules, Vested Options may be exercised during the period starting on the Vesting Date and ending on the tenth (10th) anniversary of the Date of Grant or such earlier or later date in accordance with the Rules of the Plan, and in particular Rules 4.7, 5.2, 5.4 and 6.4.
		
	 Date on which Options will in any
 event
lapse:
	 	The Options will lapse on the tenth (10th) anniversary of the Date of Grant (insert date) or in specific circumstances as stated in the Rules of the
Plan, and in particular Rules 4, 5 and 8 of the Plan.

 If you wish to accept this Grant you can do so by returning a signed copy of this Notice of Grant to ProQR Therapeutics N.V.
(the “Company”) within 14 days from the date of this Notice of Grant. If the Company will not have received a duly signed letter on that date, the Grant will be null and void such that the offer will lapse automatically with immediate
effect and without any consideration becoming due. 
  

	
	Yours sincerely,
	
	ProQR Therapeutics N.V.
	
	By
	Title:

  
 Page 1 of 2 

 Statement Participant 

By placing my signature below, I hereby confirm that I accept the offer of a Grant of Options on the date shown above, subject to the terms and conditions and
as formally described in the Rules of the Plan and all other statutory regulations that are or become applicable with regard to the granted Options. 
 I
further acknowledge receipt of a copy of the Rules and I will act in accordance with all of the terms and conditions of the Options, the Rules and the Insider Trading Rules. 

I consent to and authorise the collection, processing, transfer and disclosure of information related to the Grant and exercise of the Options (including
information regarding my date of birth, commencement date of employment and details regarding the Options and any similar rights previously granted to me by the Company.) to the Company or to any third party retained by the Company to administer the
exercise of the Options and to any governmental or regulatory authorities in The Netherlands or elsewhere. 
 I have been informed that the purpose of the
transfer of this information is to allow me to exercise the Options in accordance with (i) the terms under which the Options were granted and (ii) applicable laws and stock exchanges and/or listing rules. I have been informed that such
information will be kept confidential and will be retained for the period of time necessary to achieve this purpose, as far as possible under the applicable laws and regulations. I have also been informed that other jurisdictions may have a
different level of data privacy protection from that which may be applicable in the Netherlands. 
 I confirm that I accept that the grant and exercise of
the Options may be subject to securities and insider trading laws and rules and stock exchange regulations and I confirm that I will act in accordance with these laws, rules and regulations. 

Insider Trading Rules apply to the Company, as stated in the Rules, especially Rule 16 of the Plan. The Insider Trading Rules are subject to change. I am
aware of the fact that these rules may contain restrictions with regard to the Grant and exercise of the Options in the future. 
 I confirm that I am aware
that the Plan and the Articles of Association are subject to change that can be effected by the Company from time to time. 
  

	
	  

	
	Name:
	
	Date:
	
	Place:

  
 Page 2 of 2 

 

 
 Notice of Exercise 

ProQR Therapeutics N.V. Stock Option Plan 
  

							
	To:	 	ProQR Therapeutics N.V.	  	
		 	Darwinweg 24	  	
		 	2333 CR Leiden, The Netherlands	  	
				
	From:	 	Mr. / Ms.	  	  
	  	
			
	Address:	 	  
	  	
			
	Postal code/place:	 	  
	  	
			
	Country:	 	  
	  	
			
	Securities account Number	 	  
	  	

 I hereby give notice to ProQR Therapeutics N.V. (the “Company”) that I wish to exercise my Options as granted to me
in the Notice of Grant, a signed and dated copy of which I attach. It regards
                    1 Options covering the same number of Shares to be issued by the Company.
Capitalised terms used herein shall have the same meaning as in the Rules of the Company’s Stock Option Plan unless expressly stated otherwise. 
 I am
aware and I acknowledge that, subject to the Rules of the Plan and any Insider Trading Rules and all other regulations and documents relating to my Options: 
  

	(a)	on exercise of my Options an obligation to pay wage withholding tax and employee social security premiums or equivalent liabilities (“Tax Liability”) may arise. Further, I am aware that the grant of my Options
was made conditionally on my undertaking to pay this Tax Liability. I agree and acknowledge that I shall be responsible for and shall indemnify the Company or the relevant Group Company against any Tax Liability. I am aware that I can choose the
manner of settlement of my tax liability. The Company or Group Company may withhold any amounts from my net pay for the relevant pay period or allow me to make such arrangements as are necessary to satisfy any Tax Liability. I can elect the
“exercise immediate sell method” or the “sell to cover method” by ticking the applicable box below. The Company will calculate the taxes due on exercise and instruct on my behalf and on my cost to sell all or a sufficient number
of Shares required to cover the tax liability. The net proceeds of such sale required to cover the tax liability will be transferred to the Company or Group Company to enable it to meet its withholding obligations. The remainder of the cash proceeds
following the exercise immediate sell method will be transferred to my bank account as known by the Company. The remainder of the Shares following the sell to cover method will be transferred to my securities account under the terms and conditions
of the Plan. I will indicate my choice of payment of taxation by ticking one of the boxes below. 

  

	(b)	the date of exercise shall be the later of the receipt by the Company of the Notice of Exercise signed by me, the payment of the Option Price and the date that the Supervisory Board states that the conditions imposed on
me have for the exercise of my Options been fulfilled, if applicable. 

  

	1 	Insert number of Options you wish to exercise 

  
 Page 1 /2 

	(c)	the exercise of the Options may be subject to securities and insider trading laws and rules and stock exchange regulations and Insider Trading Rules and I confirm that I will act in accordance with these laws, rules and
regulations and Insider Trading Rules. I am aware of the fact that these rules may contain restrictions with regard to the Grant and exercise of the Options. Where any exercise would temporarily be prohibited by law, securities regulations, or any
Insider Trading Rules, the Exercise Period shall be extended with the length of such period of prohibition provided that an Option may not be exercised after the expiry of the Option in accordance with the Rules of the Plan, but in particular Rule
6.4 of the Plan. 

 I declare that I make the following election with respect to the exercised Options in order to meet the tax liability:

  

	 	 ̈	Payment of taxes upon request of my employer. Please instruct the Company or the relevant Group Company to send me a request for payment of taxes and I will pay the amount of taxes due to my employer within [15] days. I
understand that at that moment all Shares will then be Released to my securities account. 

  

	 	 ̈	Payment of taxes by withholding such taxes from my monthly gross salary in the month of the exercise of the Options and / or the subsequent month. By ticking this box I give consent to the Company or Group Company to
apply the required tax withholdings. I understand that at that moment all Shares will then be Released to my securities account. 

  

	 	 ̈	Sell to cover method. Please instruct the designated party by the Company to sell sufficient Shares acquired following the exercise of the Options to cover the tax and/or social security liabilities due upon this
exercise. I know that the transaction cost is for my account. I also realise that the number of Shares that will be Released to my securities account is lower than the number of Shares at the exercise of the Option. 

 

	 	 ̈	Exercise immediate sell method. Please instruct the designated party by the Company to sell all the Shares acquired following the exercise of the Options. The net proceeds of such sale required to cover the tax and/or
social security liability due upon this exercise will be transferred to the Company or Group Company. The remainder of the net proceeds will be transferred to my bank account as known by the Company. I know that the transaction cost is for my
account. 

  

	
	  

	
	Name:
	
	Date:
	
	Place:

  
 Page 2/2EX-10.3

 Exhibit 10.3 

MANAGEMENT SERVICES AGREEMENT 

THE UNDERSIGNED 
  

	1.	ProQR Therapeutics B.V., a private company with limited liability incorporated under the laws of the Netherlands (in Dutch: besloten vennootschap), having its corporate seat at Leiden, the Netherlands and
its registered address at Darwinweg 24 (2333 CR) Leiden, the Netherlands, registered with the Dutch Trade Register under number 54600790 (hereinafter: “ProQR”); 

and 
  

	2.	Mr D.A. (Daniël Anton) de Boer, born in Haarlem, the Netherlands on 12 April 1983, residing at Diermenseweg 3 (3882 RX) Putten, the Netherlands (hereinafter: “De Boer”);

 each hereinafter a “Party” and collectively the “Parties”. 

WHEREAS 
  

	A.	De Boer has been employed by ProQR since 1 April 2012 on the basis of an employment agreement dated 2 October 2013 in the position of Chief Executive Officer. 

 

	B.	De Boer has been appointed as statutory director (in Dutch: statutair bestuurder) of ProQR with effect from 21 February 2012 for an indefinite period of time. 

 

	C.	It is contemplated that ProQR will be converted to a public company with limited liability (in Dutch: naamloze vennootschap) and, subsequently, that ProQR’s ordinary shares will be listed and admitted
to trading on the NASDAQ Global Market (hereinafter: the “IPO”). Effectuation of the IPO is currently envisaged to be end September 2014. 

  

	D.	Pursuant to article 2:132 subsection 3 of the Dutch Civil Code (in Dutch: Burgerlijk Wetboek) (hereinafter: the “DCC”) - as introduced by the Management and Supervision Law Act (in Dutch:
Wet Bestuur & Toezicht) that took effect on 1 January 2013 - the contractual legal relationship between a listed company and its statutory director shall not be regarded as an employment agreement. 

	E.	Considering the above, the Parties wish to conclude and set out the terms and conditions governing their relationship in this management services agreement (hereinafter: the “Agreement”), subject
to occurence of the IPO and with effect from the actual date thereof. 

  

	F.	This Agreement is an agreement for the provision of services (in Dutch: overeenkomst van opdracht) as defined in clauses 7:400 et seq. DCC. 

 

	G.	Upon effectuation of this Agreement, this Agreement replaces and supersedes the employment agreement between the Parties dated 2 October 2013, which consequently shall be deemed to have been terminated and
shall no longer exist as from that moment. 

  

	H.	In accordance with article 2:132 subsection 3 DCC, the Parties confirm that they do not have the intention to conclude an employment agreement and that this Agreement cannot be deemed an employment agreement.

 HEREBY AGREE AS FOLLOWS 
  

	1.	Term and duration of this Agreement  

  

	1.1.	This Agreement shall come into effect subject to occurrence of the IPO and as of the actual date thereof. 

  

	1.2.	This Agreement has been concluded for the term of the appointment of De Boer as statutory director and shall expire by operation of law, without any prior notice being required, at the moment when the appointment as
statutory director expires. If at any time De Boer is re-appointed as statutory director by ProQR’s General Shareholders’ Meeting (hereinafter: the “GSM”), this Agreement shall be extended for the term of the
re-appointment, after which it shall again expire by operation of law without any prior notice being required. 

  

	1.3.	Each Party may at all times terminate this Agreement by giving written notice to the other Party before the end of a calendar month, subject to a two (2) months’ notice period for both Parties, unless written
notice of termination is given for urgent cause in which case no notice period applies for the Party giving notice. For the definition of urgent cause, use will be made of the definition of urgent cause (in Dutch: dringende reden) in article
7:678 DCC (hereinafter: “Urgent Cause”). 

  
 2 

	1.4.	For the purpose of a termination of this Agreement as set forth in clause 1.3, the dismissal or the resignation of De Boer as statutory director of ProQR shall be deemed a termination of this Agreement by operation of
law without any prior notice being required, which termination shall take effect (i) as per the date two months after the date on which the GSM has adopted the resolution pursuant to which De Boer shall be dismissed or (ii), as the case may be,
as per the date two months after the date on which De Boer has submitted his written resignation statement. In deviation from the previous sentence, this Agreement shall terminate with immediate effect as from the date per which (i) the GMS has
dismissed De Boer as statutory director, or (ii) as the case may be, De Boer has resigned as statutory director, in the event such dismissal or resignation (as the case may be) is given/made for Urgent Cause. 

 

	1.5.	Should one of the Parties terminate this Agreement without taking into account the relevant notice period as prescribed in clause 1.3, while such termination is not given by the relevant Party for Urgent Cause, the
other Party may demand a fixed compensation equal to two (2) times De Boer’s monthly fixed compensation as set forth in clause 2.1. 

  

	1.6.	In the event that a situation as set forth in clause 1.5 occurs, this Agreement will keep its legal effect in full. 

  

	2.	Compensation  

  

	2.1.	De Boer’s fixed annual compensation (including holiday allowance) shall amount to €250,000 gross per year, to be paid in twelve equal monthly instalments, and shall be paid before the end of each calendar
month in anticipation of the mandatory tax and social security withholdings and agreed deductions. 

  

	2.2.	ProQR’s supervisory board (in Dutch: raad van commissarissen) shall reconsider and, if deemed necessary, increase the fixed annual compensation of De Boer on an annual basis, in accordance with the terms and
conditions of ProQR’s compensation policy. 

  

	3.	Bonus and ESOP Plan 

  

	3.1.	 De Boer shall be eligible to an annual bonus, in accordance with the conditions in that respect as prescribed by ProQR’s compensation policy, as

  
 3 

	 	
amended from time to time by the GSM and/or ProQR’s supervisory board. 

  

	3.2.	De Boer will be entitled to participate in ProQR’s amended and restated ESOP Plan, on the terms and conditions determined by the compensation committee, in accordance with ProQR’s compensation policy.

  

	4.	Expenses and cell phone  

  

	4.1.	All necessary expenses incurred by De Boer in the course of performing his work shall be reimbursed by ProQR upon submission of an itemised expense claim with receipts. 

 

	4.2.	ProQR shall provide De Boer with a cell phone. All costs relating to the use of this telephone shall be borne by ProQR. 

  

	5.	Holiday entitlement 

 De Boer shall be entitled to 30 days’ holiday per year.

  

	6.	Health insurance 

 ProQR shall contribute to De Boer’s health insurance to
the extent legally required. 
  

	7.	Illness 

  

	7.1.	With regard to reporting illness and the illness itself, De Boer shall follow the instructions given, and which, in the future, may be given, in writing by ProQR. 

 

	7.2.	If De Boer is prevented from carrying out his work as a result of illness, ProQR shall continue to pay 70% of De Boer’s fixed monthly compensation as in force at that time for a maximum of twenty-four
(24) months and, during that period, ProQR shall not terminate this Agreement, unless an Urgent Cause occurs. 

  

	7.3.	After the period of twenty-four months as set forth in clause 7.2, ProQR’s right to terminate this Agreement as set forth in clause 1 shall regain its effect. 

  
 4 

	7.4.	If ProQR makes use of its right to terminate this Agreement after twenty-four months of illness by giving written notice of such termination to De Boer, ProQR will observe a notice period of two (2) months. If this
situation occurs and insofar De Boer is still a statutory director of ProQR, De Boer shall submit to the GSM a written resignation statement whereby he resigns as statutory director of ProQR no later than on the day this Agreement ends.

  

	7.5.	For the purpose of this clause 7, periods of illness (whether the incapacity for work is full or partly) that follow each other within less than four (4) weeks in between, shall be deemed one and the same period of
incapacity for work. 

  

	7.6.	De Boer shall not be entitled to the payment referred to in clause 7.2, if and to the extent that in connection with his illness, he can validly claim damages from a third party on account of loss of compensation. In
this event, ProQR shall satisfy payment solely by means of an advanced payment on the compensation to be received from the third party and upon assignment by De Boer of his rights to damages vis-à-vis the third party concerned up to the total
amount of advanced payments made. The advanced payments shall be set-off by ProQR if the compensation is paid or, as the case may be, in proportion thereto. 

  

	8.	Job performance 

  

	8.1.	De Boer shall perform his job as Chief Executive Officer and statutory director to the best of his ability and in accordance with the norms and procedures of ProQR’s group as amended from time to time. De Boer is
obliged to do or refrain from doing all that statutory directors in similar positions should do or should refrain from doing. De Boer shall devote himself, his time and his energy to promoting the interest of ProQR and its affiliates.

  

	8.2.	In his capacity as statutory director of ProQR De Boer shall have all rights and obligations (to be) granted to and imposed on him by law or by or pursuant to the articles of association (in Dutch: statuten) of
ProQR (hereinafter: the “Articles of Association”). By signing this Agreement, De Boer declares that he is familiar with the content of the Articles of Association and that he shall adhere thereto. In addition, De Boer shall adhere
to ProQR’s Board Regulations (in Dutch: Bestuursreglement), ProQR’s general business principles and all other applicable ProQR policies and guidelines, each document as amended by ProQR from time to time. 

  
 5 

	8.3.	The position as statutory director of ProQR may require that De Boer also acts as statutory or supervisory director of the business(es) (to be) affiliated with ProQR without receiving any additional compensation. When
De Boer ceases to be statutory director of ProQR, he shall resign (unless otherwise agreed between ProQR and De Boer) from the aforementioned positions with effect from a date to be determined by ProQR. 

 

	8.4.	De Boer shall also carry out other activities if, in the opinion of ProQR, ProQR’s business so requires. 

  

	8.5.	De Boer shall perform his activities at ProQR’s offices or such other place as ProQR may instruct. 

  

	8.6.	De Boer’s regular working hours shall be 40 per week. If ProQR deems this necessary, De Boer shall be required to work overtime. 

 

	8.7.	If De Boer carries out activities on behalf of enterprises affiliated with ProQR, payment for these activities shall be considered to be included in De Boer’s compensation as set out in article 2.1.

  

	9.	Pension 

 De Boer shall be included in the pension scheme of ProQR under the
conditions set therein. 
  

	10.	Tax/ Social Security Liability for Benefits 

 If one or more of the above benefits
is subject to the levy of income tax and/or social security premiums under the 2001 Income Tax Act and/or the social security laws, the relevant tax and social security premiums shall be borne by De Boer. 

 

	11.	Ancillary Activities 

 De Boer may not perform any ancillary activities, paid or
unpaid, in whatever form or manner, without ProQR’s prior written permission. 
  

	12.	Confidentiality 

 Both throughout the duration and after the termination of this
Agreement, De Boer shall maintain the confidentiality of all confidential information 

  
 6 

 
known to him concerning ProQR. This duty of confidentiality shall extend to all confidential information pertaining to enterprises affiliated with ProQR and clients and other business relations
of ProQR. Confidential information is any information that has not already come into the public domain. 
  

	13.	Company’s Property 

  

	13.1.	All items, including written documents, computer files and data carriers, obtained by De Boer from or on behalf of ProQR or an enterprise affiliated with ProQR during the period that this Agreement is in effect, are and
shall remain the property of ProQR or the affiliated enterprise, respectively. 

  

	13.2.	De Boer shall return such items to ProQR at first request or, in the absence of such a request, no later than the day on which this Agreement terminates, and De Boer shall not withhold any copy thereof or therefrom.

  

	14.	Intellectual Property 

  

	14.1.	De Boer will transfer all the intellectual and/or industrial property rights arising from his work to ProQR irrespective of whether the creation, discovery or invention took place during or outside working hours and
irrespective of whether De Boer’s position either directly or indirectly entails creative, exploratory or inventive work, including the creation of intellectual property, as soon as they are created, in so far as these rights do not already
rest with ProQR in accordance with the law. De Boer hereby transfers all intellectual property rights to ProQR and ProQR hereby accepts such transfer. Insofar as necessary to effectuate such transfer De Boer shall, at ProQR’s first request,
co-operate and perform all actions that ProQR may deem desirable or necessary to effectuate or formalize such transfer. De Boer confirms that he transfers, to the extent permitted by applicable law, all (future) moral rights he may possess or
acquire as a consequence of the performance of his duties under this Agreement. Insofar as De Boer’s moral rights cannot be assigned or transferred due to provisions of mandatory law, De Boer hereby, insofar as permitted by mandatory law,
waives such moral rights. 

  

	14.2.	 De Boer shall immediately report all creations, discoveries and inventions to ProQR, and shall do everything necessary to make possible the
acquisition 

  
 7 

	 	
by, or transfer to, ProQR of any intellectual property rights in that regard. 

  

	14.3.	De Boer shall do whatever may be required on his part to obtain the maximum possible protection of such intellectual property. 

  

	14.4.	De Boer acknowledges that his compensation includes compensation for all creations, discoveries and inventions made, solely or jointly, by him, including the creation of intellectual property. 

 

	15.	Non-competition clause 

  

	15.1.	During the term of this Agreement, De Boer shall not be engaged in any activities (other than pursuant to this Agreement or other agreements) which are the same as or similar to the activities of ProQR. This includes
the acquisition or ownership of shares or depository receipts for shares in enterprises carrying on the same or similar activities as those of ProQR or enterprises affiliated therewith, excluding shares officially listed on a stock exchange.

  

	15.2.	It is acknowledged that at the request of De Boer, the provisions of this non-competition clause for certain specific activities as agreed with De Boer, can be waived pursuant to a decision of the GSM holding at least
66 2/3% of all shares. 

  

	15.3.	The provisions of this non-competition clause are waived for the following activities of De Boer: 

  

	 	•	 	board member of Stichting ProQR Therapeutics Participation 

  

	 	•	 	board member of Stichting Administratiekantoor Friends of ProQR; and 

  

	 	•	 	shareholder of Appel B.V. 

  

	15.4.	In the event that this Agreement terminates, the above provisions of this non-competition clause shall no longer apply (for the avoidance of doubt: also if De Boer is still a shareholder of ProQR). 

 

	16.	Non solicitation 

 During this Agreement as well as for a period of one year after
the termination date of this Agreement, De Boer shall refrain from, either directly or indirectly: 

  
 8 

	 	i.	engaging individuals who are on the payroll of ProQR or any enterprise affiliated with ProQR or who were so during De Boer’s service for ProQR; 

 

	 	ii.	soliciting or entering into commercial relationships with any person or entity which is a client of ProQR at the date on which this Agreement terminates, or was a client during the three year period prior to that date
even if such contact is initiated by these customers or relations. 

  

	17.	Penalty Clause 

 In the event of a breach of any of the provisions of articles 11
up to and including 16, De Boer shall be liable to ProQR for an immediately due and payable penalty of EUR 5,000 per breach and EUR 1,000 for each day on which the breach continues, without prejudice to any other rights provided for by law or
under this Agreement such as the right to specific performance, the right to an injunction or the right to claim damages in lieu of this penalty. 
  

	18.	Compensation upon termination 

  

	18.1.	If within two (2) years following a ‘change of control’ (as defined below in article 18.2) this Agreement is terminated at the initiative of ProQR other than for ‘cause’ (as defined below
article 18.2), De Boer shall be entitled to a compensation of 24 months’ gross compensation, calculated on the basis of De Boer’s last earned gross monthly fixed compensation (thus excluding other monthly or yearly emoluments or
compensation, such as (holiday) allowances, thirteenth month, (pension) contributions, commission, bonus or fringe benefits). For the avoidance of doubt, De Boer shall not be entitled to said compensation if this Agreement is terminated within two
years following a change of control (i) by operation of law upon expiry of De Boer’s period of appointment as statutory director; or (ii) after a period of continuous illness of two (2) years on the part of De Boer.

  

	18.2.	For the purpose of article 18.1: 

  

	 	a.	 a “change of control” shall exist and deemed to have occurred if a third party or third parties acting together has acquired
(i) at least two thirds (i.e. at least 66.7 %) of the shares or the voting 

  
 9 

	 	
rights relating to such shares, in the outstanding share capital of ProQR; or (ii) all or substantially all of the business of ProQR, provided that future (venture capital) financing rounds,
an IPO or subsequent listing of ProQR or a transfer of voting rights pursuant to a share pledge, shall not be deemed to constitute a change of control. 

  

	 	b.	“cause” shall exist of (i) dismissal for an Urgent Cause; or (ii) dismissal for underperformance of De Boer or circumstances that are predominantly attributable to De Boer. 

 

	18.3.	If a right to compensation pursuant to article 18.1 has materialised, the compensation shall be paid by ProQR within one (1) month of the termination of this Agreement in a manner to be specified by De Boer, as
long as this manner of payment is within the bounds of tax legislation. The manner of payment will not result in cost or tax increases for Company. 

  

	19.	Amendments 

  

	19.1.	In the event that it has a substantial interest in doing so, ProQR shall be entitled to unilaterally amend one or more of the provisions of this Agreement. 

 

	19.2.	A substantial interest may also be deemed to exist, inter alia, if 

  

	 	i.	there is a change of control of ProQR’s enterprise or of the group to which ProQR belongs, or a transfer of the enterprise or a part thereof within the meaning of article 7:662 DCC; 

 

	 	ii.	the costs of the insurances of De Boer to which ProQR contributes pursuant to this Agreement increase. 

  

	20.	Governing law 

 This Agreement is governed by and construed in accordance with the
laws of the Netherlands. 
  

	21.	Final provision 

 No amendment and/or addition to this Agreement shall have any
force or effect unless it is in writing. This Agreement supersedes all previous 

  
 10 

 
agreements between the parties. 

  
 11 

 Agreed and signed in duplicate at
                     on                     .

 on behalf of 
 ProQR Therapeutics B.V. 

 

					
	  
	 		 	  

	Name:	 		 	Mr D.A. de Boer
	Title:	 		 	

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]